Pfizer: Obesity ASPIRE (LOI)

funding is available for research into:

• Pathophysiology and biology of overweight and obesity:
• Understanding obesity as a disease:
• Utilising retrospective databases, generate evidence of optimal management of obesity and co-existing comorbid conditions, such as obesity in patients with heart failure, renal disease, metabolic and chronic diseases, cardiovascular disease, psychiatric diseases, orthopaedic or other musculoskeletal diseases, physical disabilities or in patients after solid organ transplantation.

Funding: up to $250,000.

https://cdn.pfizer.com/pfizercom/2021-09/2021-2022%20Global%20Obesity%20ASPIRE.pdf?K5KIDbSHZmOf8xK_JkpHapTbEfbFP2DU

https://www.pfizer.com/purpose/independent-grants/competitive-grants